Hits:
Indexed by:期刊论文
Date of Publication:2021-01-30
Journal:JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
Volume:140
Issue:46
Page Number:15820-15826
ISSN No.:0002-7863
Key Words:Biocompatibility; Diagnosis; Diseases; Energy transfer; Forster resonance energy transfer; Infrared devices, Amplified light; Cancer diagnosis; Cellular uptake; Intravenous injections; Orders of magnitude; Photodynamic therapy (PDT); Therapeutic index; Tumor targeting, Photodynamic therapy, article; biocompatibility; cancer model; controlled study; energy transfer; gene amplification; human; in vitro study; in vivo study; infrared radiation; intravenous drug administration; light harvesting system; mitochondrion; photosensitization; therapeutic index; tumor ablation
Abstract:Structure-inherent targeting (SIT) agents are of particular importance for clinical precision medicine; however, there still exists a great lack of SIT phototheranostics for simultaneous cancer diagnosis and targeted photodynamic therapy (PDT). Herein, for the first time, we propose a "one-for-all" strategy by using the Forster resonance energy transfer (FRET) mechanism to construct such omnipotent SIT phototheranostics. Of note, this novel tactic can not only endow conventional sensitizers with highly effective native tumor-targeting potency but also simultaneously improve their photosensitization activities, resulting in dramatically boosted therapeutic index. After intravenous injection of the prepared SIT theranostic, the neoplastic sites are distinctly "lighted up" and distinguished from neighboring tissues, showing a near-infrared signal-to-background ratio value as high as 12.5. More importantly, benefiting from the FRET effect, markedly amplified light harvesting ability and 102 production are demonstrated. Better still, other favorable features are also simultaneously achieved, including specific mitochondria anchoring, augmented cellular uptake (>13-fold), as well as ideal biocompatibility, all of which allow orders-of-magnitude promotion in anticancer efficiency both in vitro and in vivo. We believe this one-for-all SIT platform will provide a new idea for future cancer precision therapy.
